Theravance M&A Monday, June 29, 2026 0.00 Neutral

Theravance Biopharma enters merger agreement with Zymeworks.

Theravance Biopharma signed an agreement and plan of merger with Zymeworks Inc., aiming to combine their biopharmaceutical operations. This M&A transaction signals a strategic consolidation in the therapeutic antibody sector.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day